Acadia Healthcare Co Stock (NASDAQ: ACHC)

Acadia Healthcare Co (NASDAQ:ACHC) Stock, Quote.Headers.trade-ideas

Acadia Healthcare Co

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.

Menlo,Park,,Ca,,Usa,-,Feb,29,,2020:,The,Boeing

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACHC

ALTM

HAFN

PRTC

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Earnings

Earnings Beats

Mid Cap

Health Care

Small Cap

Management

Analyst Ratings

General

AVNS

ENSG

LMAT

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA.

Acadia Healthcare Expands Behavioral Health Services in Iowa

Tokyo,,Japan,-,November,21,,2018:,A,Shake,Shack,Fast

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

RGEN

SHAK

ZETA

Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Check if they&#39;re in your portfolio!

Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday.
Shares of Dyne Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NYSE">DYN</a>) fell sharply in today's pre-market trading after the company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement <a href="https://www.benzinga.com/quote/DYN">in multiple cohorts.</a>
Dyne Therapeutics shares dipped 15.6% to $38.89 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares fell 7.2% to $76.07 in pre-market trading.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares fell 5.8% to $35.70 in pre-market trading. Vice President Kamala Harris has expressed her support for American ownership of United States Steel, amidst ongoing foreign acquisition attempts.</li>
<li>Diversified Energy Company PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) fell 5.6% to $11.54 in pre-market trading. Keybanc analyst Tim Rezvan, last week, initiated coverage on Diversified Energy with an Overweight rating and announced a price target of $18.</li>
<li>LG Display Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPL#NYSE">LPL</a>) shares fell 4.4% to $3.96 in pre-market trading.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) shares declined 4.1% to $2.60 in pre-market trading.</li>
<li>Hafnia Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NASDAQ">HAFN</a>) fell 4.1% to $7.43 in pre-market trading.</li>
<li>BHP Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) shares fell 4% to $52.90 in pre-market trading</li>
<li>Hafnia Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NYSE">HAFN</a>) fell 3.4% to $7.48 in pre-market trading.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares declined 3.2% to $21.78 in pre-market trading. PureTech Health, last week, reported a year-over-year decrease in H1 financial results.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares slipped 2.6% to $169.15 in pre-market trading  ahead of the Sept. 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Acadia Healthcare Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achc#NASDAQ">ACHC</a>) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA. Plans to establish the hospital were announced in July 2023 as part of the joint-venture partnership between ACHC and Omaha-based Methodist Health System. The Methodist Jennie Edmundson Hospital is part of Methodist Health System.&nbsp;
The new facility will be named Methodist Jennie Edmundson Behavioral Health and is likely to commence operations in 2026. It will feature 96 inpatient beds, with 24 specifically designated for addressing the mental health needs of children and adolescents. It will also offer intensive outpatient services. The hospital will invest in cutting-edge technology and resources to enhance access to high-quality behavioral health services for patients dealing with acute mental health and substance use disorders.
This, in turn, is expected to bring about improved health outcomes for residents of western Iowa and eastern Nebraska. Working closely with local organizations, hospitals and first responders of the two regions will enable the joint venture partners to better serve the targeted regions.
<h2>A Time-Opportune Move on ACHC&#39;s Part</h2>
Opening the Methodist Jennie Edmundson Behavioral Health Hospital is likely to be a time-opportune move considering the dire need for acute and intensive outpatient behavioral health services across the Council Bluffs community. According to the American Hospital Directory, there remains a shortage of more than 300 inpatient behavioral health beds in Iowa and Nebraska, which further substantiates the timeliness of the recent move.
<h2>Benefits to Acadia Healthcare</h2>
New facilities resulting from joint ventures offer a means for ACHC to serve a greater number of patients and earn more revenues.&nbsp;
Acadia Healthcare often resorts to buyouts or joint ventures with renowned U.S. health systems to inaugurate new hospitals or expand existing facilities through bed additions. Its healthcare portfolio comprised 258 behavioral healthcare facilities across 38 states and Puerto Rico as of June 30, 2024. Management anticipates adding more than 400 beds to existing facilities in 2024.
<h2>ACHC Stock&#39;s Price Performance</h2>
Shares of Acadia Healthcare have gained 19.2% in the past month compared with the industry&#39;s 8.5% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4d/75809.jpg?v=356746199" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Key Picks</h2>
ACHC currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the Medical space are LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>)&nbsp;, Avanos Medical, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avns#NYSE">AVNS</a>) and The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>). While LeMaitre Vascular sports a Zacks Rank #1 (Strong Buy), Avanos Medical and Ensign Group carry a Zacks Rank #2 (Buy) at present.
LeMaitre Vascular&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 8.87%. The Zacks Consensus Estimate for LMAT&#39;s 2024 earnings implies an improvement of 37% while the same for revenues indicates growth of 13% from the respective 2023 figures.
The Zacks Consensus Estimate for LMAT&#39;s&nbsp; earnings has moved 4.5% north in the past 30 days. Shares of LeMaitre Vascular have gained 2.4% in the past month.
Avanos Medical&#39;s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 5.69%. The Zacks Consensus Estimate for AVNS&#39; 2024 earnings indicates a 35% rise from the 2023 figure.
The consensus mark for AVNS&#39;&nbsp; earnings has moved 0.7% north in the past 30 days. Shares of Avanos Medical have gained 6.1% in the past month.
Ensign Group&#39;s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.40%. The Zacks Consensus Estimate for ENSG&#39;s 2024 earnings indicates an 14.1% rise while the same for revenues implies an improvement of 13.1% from the respective 2023 reported figures.&nbsp;
The consensus mark for ENSG&#39;s earnings has moved up 0.7% in the past 30 days.&nbsp; Shares of Ensign Group have gained 1.8% in the past month.
<a href="https://www.zacks.com/stock/news/2328512/acadia-healthcare-expands-behavioral-health-services-in-iowa?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328512">To read this article on Zacks.com click here.</a>

Cantor Fitzgerald analyst Sarah James reiterates Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and maintains $90 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Neutral on Acadia Healthcare Co, Maintains $90 Price Target

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.0, a high estimate of $94.00, and a low estimate of $75.00. A decline of 0.12% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1724086828_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Acadia Healthcare Co's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Acadia Healthcare Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Acadia Healthcare Co's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.85% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching 2.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.4%, the company showcases effective utilization of assets.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Acadia Healthcare Co

Acadia Healthcare Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NYSE">ACHC</a>) short percent of float has fallen 6.19% since its last report. The company recently reported that it has 3.58 million shares sold short, which is 3.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Acadia Healthcare Co Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723058110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Acadia Healthcare Co has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Acadia Healthcare Co's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Acadia Healthcare Co's peer group average for short interest as a percentage of float is 6.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Acadia Healthcare Co's Recent Short Interest

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares jumped 65.95%. The company reached a supply agreement with Corning for next-generation fiber-optic cables to <a href="https://www.benzinga.com//node/40104952" target="_blank" rel="noreferrer noopener">support AI demands in data centers</a>.</li>
<li>Shake Shack, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) shares escalated 19.52% after the company reported <a href="https://www.benzinga.com//node/40104675" target="_blank" rel="noreferrer noopener">better-than-expected Q2 sales results</a>. Several analysts increased <a href="https://www.benzinga.com//node/40131307" target="_blank" rel="noreferrer noopener">their forecasts for the company</a>.</li>
<li>Parsons Corp NYSE: PSN) stock gained 15.42% after it reported better-than-expected Q2 results and raised its FY24 revenue outlook.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) stock increased 15.23% after the company reported better-than-expected Q2 sales results and issued Q3 and FY24 <a href="https://www.benzinga.com//node/40081350" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>.</li>
<li>Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) stock upped 15.14%. The company reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40044492/repligen-lowers-guidance-on-china-weakness-analyst-expects" target="_blank" rel="noreferrer noopener">Q2 earnings</a>, after which several analysts revised their price forecasts.</li>
<li>Frontdoor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) stock gained 15.09% following better-than-expected Q2 earnings.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock upped 14.47% after the company reported better-than-expected Q2 financial results and <a href="https://www.benzinga.com//node/40021917" target="_blank" rel="noreferrer noopener">raised its FY24 revenue guidance</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the" target="_blank" rel="noreferrer noopener">MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/24/08/40150236/doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-other" target="_blank" rel="noreferrer noopener">DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by YAO23 via Shutterstock

Deutsche Bank analyst Pito Chickering maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Hold and raises the price target from $70 to $75.

Deutsche Bank Maintains Hold on Acadia Healthcare Co, Raises Price Target to $75

Throughout the last three months, 9 analysts have evaluated Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.67, a high estimate of $94.00, and a low estimate of $83.00. Highlighting a 2.18% decrease, the current average has fallen from the previous average price target of $91.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1722614465_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Acadia Healthcare Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>Get to Know Acadia Healthcare Co Better</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Acadia Healthcare Co: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.06% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Acadia Healthcare Co's ROE stands out, surpassing industry averages. With an impressive ROE of 2.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Acadia Healthcare Co's ROA excels beyond industry benchmarks, reaching 1.4%. This signifies efficient management of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average at 0.69, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Acadia Healthcare Co Through The Eyes Of 9 Analysts

Barclays analyst Andrew Mok maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Overweight and lowers the price target from $89 to $83.

Barclays Maintains Overweight on Acadia Healthcare Co, Lowers Price Target to $83

U.S. stocks were lower, with the Dow Jones index falling over 500 points on Thursday.
Shares of Air Products and Chemicals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) rose sharply during Thursday's session after the company reported better-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/08/40100921/air-products-q3-win-eps-surge-and-margin-expansion-set-stage-for-promising-q4">adjusted EPS results</a>.
Air Products reported third-quarter 2024 adjusted EPS of $3.20, up 7% year-over-year, beating the consensus of $3.03. Sales declined 2% YoY to $2.986 billion, missing the consensus of $3.035 billion due to 2% unfavorable currency and 1% lower energy cost pass-through.
Air Products shares jumped 11.4% to $293.82 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares surged 26.2% to $3.9750. Corning and Lumen reached a supply agreement on next-generation fiber-optic cable to support data center AI demands.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) jumped 24.3% to $56.80 after the company reported better-than-expected second-quarter financial results. Also, the company announced an exclusive license agreement with TwinStrand Biosciences.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) gained 22.3% to $35.71 after the company reported better-than-expected second-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) climbed 17.8% to $103.22 after the company reported better-than-expected second-quarter sales results.</li>
<li>Clearwater Analytics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NASDAQ">CWAN</a>) gained 17.5% to $22.97 after the company reported better-than-expected second-quarter sales results and issued FY24 revenue guidance above estimates..</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) jumped 15.8% to $9.12.</li>
<li>C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) gained 15.1% to $102.48 after the company reported better-than-expected second-quarter adjusted EPS results.</li>
<li>Energy Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) gained 14.7% to $16.72 following upbeat quarterly results.</li>
<li>Frontdoor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) gained 14.2% to $45.06 following better-than-expected second-quarter financial results.</li>
<li>Hawkins, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) rose 14.1% to $118.53 following upbeat quarterly results.</li>
<li>Ranpak Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NASDAQ">PACK</a>) gained 12.7% to $8.14 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) rose 12.4% to $24.07 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue guidance above estimates. Additionally, Morgan Stanley and Oppenheimer raised their respective price targets on the stock.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) rose 12.2% to $72.73 after the company reported better-than-expected quarterly financial results..</li>
<li>FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) gained 12% to $65.34 following quarterly financial results..</li>
<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) rose 10.6% to $262.60 after the company reported better-than-expected quarterly financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) gained 9.5% to $145.82 after the company reported better-than-expected quarterly financial results.</li>
<li>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) gained 5.8% to $73.46 after the company reported better-than-expected second-quarter adjusted EPS results and raised its FY24 adjusted EPS above estimates. Additionally, the company announced the authorization of a $5 billion share repurchase program..</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rose 5.8% to $502.20 following better-than-expected quarterly earnings.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

Intraday Update

ALNY

APTV

CHRW

CVNA

ERII

EXAS

OMCL

PACK

Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday

WIIM

Acadia Healthcare shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance

Acadia Healthcare Sees FY24 Adj. EPS $3.45-$3.65 Vs $3.49 Est.; Revenue $3.180B-$3.22B Vs $3.202B Est.

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.87 by 4.6 percent. The company reported quarterly sales of $796.040 million which beat the analyst consensus estimate of $784.448 million by 1.48 percent. This is a 8.85 percent increase over sales of $731.337 million the same period last year.

Acadia Healthcare Co Q2 2024 Adj. EPS $0.91 Beats $0.87 Estimate, Sales $796.040M Beat $784.448M Estimate

Investor-owned psychiatric hospital chains increasingly operate under nonprofit brands, a strategy that has raised eyebrows among industry analysts and healthcare advocates.
Universal Health Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) and Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) are prominent players.
STAT News&#8217; investigation <a target="_blank" href="https://www.statnews.com/2024/07/08/psychiatric-hospital-investor-owned-chains-operate-under-nonprofit-brands/" rel="noreferrer noopener">reveals</a> that a Columbus Police sergeant called for action against Mt. Carmel Behavioral Health, run by Acadia Healthcare, highlighting a series of alarming incidents at the psychiatric hospital.
The sergeant&#8217;s February letter outlines a disturbing pattern of violence, prompting concerns about patient and staff safety.
Over the past six months, the hospital has witnessed over 20 emergency calls detailing horrific incidents.
This level of violence is unprecedented, especially for an institution affiliated with the local Catholic health system.
Despite its affiliation with Mount Carmel, the hospital is managed by Acadia Healthcare, a prominent publicly traded chain known for operating psychiatric facilities amidst accusations of inadequate staffing and training.
This operational environment has raised significant concerns about patient care standards and safety protocols within Acadia&#8217;s facilities nationwide.
The sergeant&#8217;s formal <a target="_blank" href="https://www.documentcloud.org/documents/24776424-cpd-complaint-1?responsive=1&amp;title=1" rel="noreferrer noopener">complaint</a> underscores longstanding issues, citing persistent physical assaults on vulnerable patients and staff.
Despite multiple engagements with the hospital&#8217;s management, concerns remain unresolved, prompting the sergeant to escalate the matter to state and national regulatory bodies, the investigation report says.
In a <a target="_blank" href="https://x.com/TaraBannow/status/1811759286881780053" rel="noreferrer noopener">post</a> on X, Tara Bannow from STAT News said, &#8220;People who worked at Acadia &amp; UHS hospitals across the country from one another said the exact same thing: There was systematic understaffing and undertraining, and our pleas to corporate were ignored.&#8221;
She adds, &#8220;What results is environments that are dangerous for patients and staff alike&#8230;Within the past year, juries issued $1 billion in verdicts against Acadia &amp; UHS.&#8221;
Price Action: ACHC shares are up 4.83% at $68.33, and UHS stock is up 2.48% at $183.12&nbsp;at the last check on Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39801282/senate-to-review-novo-nordisks-levemir-insulin-discontinuation" target="_blank" rel="noreferrer noopener">Senate To Review Novo Nordisk&#8217;s Levemir Insulin Discontinuation</a></li>
</ul>
Image via Unsplash

Large Cap

Legal

UHS, Acadia Healthcare Navigate Scrutiny Amid Safety Concern Allegations At Psychiatric Hospitals, Operating As Nonprofit

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $85.62, a high estimate of $94.00, and a low estimate of $70.00. Highlighting a 9.87% decrease, the current average has fallen from the previous average price target of $95.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1719932494_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Acadia Healthcare Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Hold</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Acadia Healthcare Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>A Deep Dive into Acadia Healthcare Co's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Acadia Healthcare Co's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 9.06%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's net margin is impressive, surpassing industry averages. With a net margin of 9.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.7%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Acadia Healthcare Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.69.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Acadia Healthcare Co Analyst Ratings

Acadia Healthcare Non-GAAP EPS of $0.91 beats by $0.03, revenue of $796M beats by $11.19M

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Raffles Medical Group (RAFLF – Research Report), C...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Raffles Medical Group (OtherRAFLF), Cencora (COR) and Acadia Healthcare (ACHC)

TD Cowen analyst Gary Taylor maintained a Buy rating on Acadia Healthcare (ACHC – Research Report) today and set a price target of $91.00. The comp...

Acadia Healthcare (ACHC) Gets a Buy from TD Cowen

Acadia Healthcare Company, Inc (ACHC) Q2 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cencora (COR – Research Report), Acadia Healthcare (...

Analysts Are Bullish on Top Healthcare Stocks: Cencora (COR), Acadia Healthcare (ACHC)

ClearBridge Small Cap Value Strategy Q2 2024 Commentary

Invesco Small Cap Growth Fund Q2 2024 Review

Small-cap and mid-cap Health Care has room to rally - Roth MKM

Acadia Healthcare is holding patients against their will to increase insurance payouts: NYT

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

AAPL

ABBV

ADBE

ADMA

ADPT

AGIO

ALGT

AMZN

ANAB

AVGO

BBIO

BDTX

BLFS

BMRN

CFCV

CORT

CRDO

CRTO

CYTK

DASH

DDOG

DLTR

EWTX

FDMT

FERG

FRSH

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

FWRD

GEHC

GKOS

GLOB

GMED

GTLB

GWRE

HALO

HLMN

ILMN

INBX

INFR

INSP

ITGR

ITRI

KNSL

LBPH

LGND

LNTH

LRGE

LSCC

MANH

MLAB

MSFT

MUSA

NAMS

NATL

NCRRP

NFLX

NTRA

NVDA

ONON

ONTO

ORIC

PEPG

PHVS

PODD

PRIM

PSCH

QDEL

RAFLF

REGN

RMBS

ROIV

RPRX

SDGR

SITE

SITM

SKYW

SRRK

SUPN

TCBX

TMDX

TMUS

TMXXF

TRVI

TSLA

TTWO

TWST

VBTX

VCEL

VKTX

WDAY

WING

YLDE

Press Releases

ACHC Investors Have Opportunity to Join Acadia Healthcare Company, Inc. Securities Fraud Investigation with the Schall Law Firm

ACADIA HEALTHCARE INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Marathon Petroleum Corporation's Directors and Officers for Breach of Fiduciary Duties – ACHC

Seven Acadia Healthcare Facilities Recognized in Newsweek's 2024 Best Addiction Treatment Center List

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Acadia Healthcare Co

Acadia Healthcare Co (ACHC) Forecast

Acadia Healthcare Co (NASDAQ:ACHC) Stock, Quote.Headers.trade-ideas